As of May 22
| -0.015 / -3.09%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +538.30% increase from the last price of 0.47.
The current consensus among 2 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.